US Supreme Court Temporarily Restores Mail Access to Abortion Drug Mifepristone
The United States Supreme Court has temporarily lifted a lower court’s restriction on the mail delivery of the abortion drug mifepristone, pending further legal arguments.
In a brief order issued on Monday, the apex court restored nationwide mail access to the drug until at least May 11, pausing a ruling of the 5th Circuit Court of Appeals. The appellate court had earlier barred mail distribution in a case brought against the Food and Drug Administration (FDA) by the state of Louisiana, which enforces some of the strictest anti-abortion laws in America.
Manufacturers of the drug, Danco Laboratories and GenBioPro, had sought urgent relief from the Supreme Court, arguing that the appellate ruling would severely disrupt access to mifepristone, which is widely used in abortion and miscarriage care.
The 5th Circuit’s decision required women to obtain the drug in person from clinics, effectively banning telemedicine prescriptions and pharmacy distribution. The Supreme Court’s intervention means the status quo remains in place while parties file legal briefs.
Mifepristone, approved by the FDA since 2000, is used alongside misoprostol to terminate pregnancies up to 70 days of gestation. It is also commonly prescribed for managing early miscarriages.
The case comes against the backdrop of the Supreme Court’s 2022 decision overturning Roe v. Wade, which had guaranteed abortion rights for nearly 50 years. Since then, more than 20 US states have enacted bans or restrictions, intensifying legal battles over reproductive health.
While abortion rights advocates welcomed the temporary reprieve, conservative groups stressed that the pause does not amount to a reversal of the appellate ruling, but only allows the justices time to consider the matter fully.
